Table 4.
Classification of pathological manifestations of MG patients who underwent kidney biopsy.
| Malignant neoplasms related lesions (N = 16) | n (%) | MGRS-related lesions (N = 43) | n (%) | MG-unrelated lesions (N = 42) | n (%) |
|---|---|---|---|---|---|
| Amyloid nephropathy | 8 (50.0%) | Amyloid nephropathy | 26 (60.5%) | MN | 16 (38.1%) |
| Glomerular minor lesion | 2 (12.5%) | MPGN | 4 (9.3%) | Diabetic glomerulosclerosis | 4 (9.5%) |
| FSGS | 1 (6.3%) | MN | 2 (4.7%) | IgA nephropathy | 3 (7.1%) |
| EPGN | 1 (6.3%) | Mesangioproliferative GN | 2 (4.7%) | FSGS | 3 (7.1%) |
| MPGN | 1 (6.3%) | Mesangial nodular sclerosing glomerulopathy | 2 (4.7%) | MPGN | 3 (7.1%) |
| LCDD | 1 (6.3%) | Subacute tubulointerstitial nephritis | 2 (4.7%) | Glomerular minor lesion | 3 (7.1%) |
| HCDD | 1 (6.3%) | C3 GN | 1 (2.3%) | Proliferative-sclerosing GN | 3 (7.1%) |
| TMA | 1 (6.3%) | EPGN | 1 (2.3%) | Subacute tubulointerstitial nephritis | 2 (4.8%) |
| LCDD | 1 (2.3%) | Hypertensive renal disease | 1 (2.4%) | ||
| TMA | 1 (2.3%) | LN | 1 (2.4%) | ||
| Proliferative-sclerosing GN | 1 (2.3%) | EPGN | 1 (2.4%) | ||
| Mesangioproliferative GN | 1 (2.4%) | ||||
| Hepatitis B virus-associated nephritis | 1 (2.4%) |
FSGS, focal segmental glomurular sclerosis; MN, membranous nephropathy; TMA, thrombotic microangiopathy; MPGN, membranoproliferative glomerulonephritis; LCDD, light chain deposition disease; HCDD, heavy chain deposition disease; EPGN, endocapillary proliferative glomerulonephritis; LN, lupus nephritis.